Our Story

Bob joined Brandon Capital in 2016.

Prior to joining Brandon Capital, Bob was Deputy Chief Medical Officer at Nucleus Network, Australia’s largest clinical trials unit. He was involved in overseeing and executing over 100 early phase clinical trials, including as Principal Investigator. He was also involved in overseeing Nucleus Network’s clinical operations, business development and expanding its trial capabilities.

During his time at Nucleus Network, he was appointed as the founding executive for Cardiora, a Brandon Capital investee company developing therapies for heart failure. He successfully led Cardiora through multiple phase 2 clinical trials. The program was subsequently licensed to a specialty pharmaceutical company.

Bob obtained his MD from The University of Melbourne and subsequently undertook his surgical residency in some of Australia’s leading academic hospitals, including the Royal Melbourne Hospital and Royal North Shore Hospital. He is a Graduate of the Australian Institute of Company Directors and currently lectures in the University of Melbourne’s MBA and Biodesign programs. Since joining Brandon, he has led investments both in Australia and in the US across therapeutic areas and also runs Brandon Capital’s training programs.